FXR induces SOCS3 and suppresses hepatocellular carcinoma
Fei Guo1, Zhizhen Xu2, Yan Zhang2
1Department of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Abstract:
Suppressor of cytokine signaling 3 (SOCS3) is regarded as a vital repressor in the liver carcinogenesis mainly by inhibiting signal transducer and activator of transcription 3 (STAT3) activity. Farnesoid X Receptor (FXR), highly expressed in liver, has an important role in protecting against hepatocellular carcinoma (HCC). However, it is unclear whether the tumor suppressive activity of FXR involves the regulation of SOCS3. In the present study, we found that activation of FXR by its specific agonist GW4064 in HCC cells inhibited cell growth, induced cell cycle arrest at G1 phase, elevated p21 expression and repressed STAT3 activity. The above anti-tumor effects of FXR were dramatically alleviated by knockdown of SOCS3 with siRNA. Reporter assay revealed that FXR activation enhanced the transcriptional activity of SOCS3 promoter. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay displayed that FXR directly bound to IR9 DNA motif within SOCS3 promoter region. The in vivo study in nude mice showed that treatment with FXR ligand GW4064 could decelerate the growth of HCC xenografts, up-regulate SOCS3 and p21 expression and inhibit STAT3 phosphorylation in the xenografts. These results suggest that induction of SOCS3 may be a novel mechanism by which FXR exerts its anti-HCC effects, and the FXR-SOCS3 signaling may serve as a new potential target for the prevention/treatment of HCC.
Insights
Farnesoid X Receptor (FXR) activation inhibits liver cancer growth by increasing Suppressor of cytokine signaling 3 (SOCS3). This FXR-SOCS3 pathway offers a new target for hepatocellular carcinoma (HCC) prevention and treatment.
Area of Science:
- Hepatology
- Molecular Biology
- Oncology
Background:
- Suppressor of cytokine signaling 3 (SOCS3) inhibits liver carcinogenesis via STAT3 signaling.
- Farnesoid X Receptor (FXR) protects against hepatocellular carcinoma (HCC).
Purpose of the Study:
- To investigate if FXR's tumor-suppressive activity involves SOCS3 regulation.
- To elucidate the molecular mechanism of FXR in HCC.
Main Methods:
- FXR activation using GW4064 in HCC cells.
- SOCS3 knockdown via siRNA.
- Reporter assays, EMSA, and ChIP assays.
- In vivo HCC xenograft studies in nude mice.
Main Results:
- FXR activation inhibited HCC cell growth, induced G1 cell cycle arrest, and repressed STAT3 activity.
- FXR enhanced SOCS3 promoter activity, directly binding to its promoter region.
- FXR activation up-regulated SOCS3 and p21 expression, inhibiting STAT3 phosphorylation in vivo.
Conclusions:
- FXR exerts anti-HCC effects through SOCS3 induction.
- The FXR-SOCS3 signaling pathway is a potential therapeutic target for HCC.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Pleiotropy
Inheritance of Chromatin Structures
TGF - β Signaling Pathway
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:


